COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00042068




Registration number
NCT00042068
Ethics application status
Date submitted
22/07/2002
Date registered
24/07/2002
Date last updated
1/11/2013

Titles & IDs
Public title
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
Scientific title
A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis
Secondary ID [1] 0 0
107.258
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Meloxicam

Treatment: Drugs: Meloxicam


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Response according to American College of Rheumatology 20% (ACR20) classification
Timepoint [1] 0 0
at 12 weeks
Secondary outcome [1] 0 0
Number of painful or tender joints
Timepoint [1] 0 0
up to 12 weeks
Secondary outcome [2] 0 0
Number of swollen joints
Timepoint [2] 0 0
up to 12 weeks
Secondary outcome [3] 0 0
Patient's global (overall) assessment of disease activity
Timepoint [3] 0 0
up to 12 weeks
Secondary outcome [4] 0 0
Investigator's global (overall) assessment of disease activity
Timepoint [4] 0 0
up to 12 weeks
Secondary outcome [5] 0 0
Patient's assessment of pain
Timepoint [5] 0 0
up to 12 weeks
Secondary outcome [6] 0 0
Patient's assessment of physical function (mHAQ)
Timepoint [6] 0 0
up to 12 weeks
Secondary outcome [7] 0 0
C-Reactive Protein (CRP)
Timepoint [7] 0 0
up to 12 weeks
Secondary outcome [8] 0 0
Withdrawal due to lack of efficacy
Timepoint [8] 0 0
up to 12 weeks
Secondary outcome [9] 0 0
Duration of morning stiffness
Timepoint [9] 0 0
up to of 12 weeks
Secondary outcome [10] 0 0
Patient's final global (overall) assessment of efficacy
Timepoint [10] 0 0
at end of 12 weeks
Secondary outcome [11] 0 0
Investigator's final global (overall) assessment of efficacy
Timepoint [11] 0 0
at end of 12 weeks
Secondary outcome [12] 0 0
Patient status with regard to change in arthritic condition
Timepoint [12] 0 0
at end of 12 weeks
Secondary outcome [13] 0 0
Use of rescue medication
Timepoint [13] 0 0
up to 12 weeks
Secondary outcome [14] 0 0
Incidence and intensity of adverse events
Timepoint [14] 0 0
until 4 weeks post treatment
Secondary outcome [15] 0 0
Patient's final global assessment of tolerability
Timepoint [15] 0 0
at end of 12 weeks
Secondary outcome [16] 0 0
Investigator's final global assessment of tolerability
Timepoint [16] 0 0
at end of 12 weeks
Secondary outcome [17] 0 0
Withdrawals due to adverse events
Timepoint [17] 0 0
at end of 12 weeks

Eligibility
Key inclusion criteria
- Age greater than or equal to 18 and less than or equal to 80

- Diagnosis of Rheumatoid Arthritis for at least six weeks

- Taking an NSAID

- If female: using adequate contraception

- Willingness to stop current NSAID until criteria reached to begin study drug

- Able to provide written informed consent
Minimum age
18 Years
Maximum age
80 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Intolerance or hypersensitivity to NSAIDs or ingredients of trial drug

- Pregnancy, lactating

- Use of investigational drug within 30 days prior to entering the trial

- History of peptic ulcer or of gastrointestinal hemorrhage except simple hemorrhoidal
bleeding

- History of cerebrovascular or other bleeding disorder

- Severe hypertension

- Other disease that might interfere with safety of the patient or evaluation of trial
drug (investigator's opinion)

- RA of functional class IV

- Synovectomy in any large joint within the past 6 months prior to entering the trial or
planned during trial

- Concomitant therapy with anticoagulant, therapeutic doses of aspirin, phenothiazines,
lithium, chronic GI-medication, analgesic drug (except acetaminophen up to 4
grams/day)

- DMARDs initiated within past three months or dose changed less than two months before
entering the trial

- Therapy with corticosteroids exceeding 10 mg/day prednisone equivalent or change in
dose within 1 month before trial

- Concomitant therapy with ACTH within past month before entering the trial.

- History of narcotic or alcohol abuse (past 12 months)

- Abnormal laboratory values

- Previous participation in the present trial

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Boehringer Ingelheim Investigational Site - Cotton Tree
Recruitment hospital [2] 0 0
Emeritus Research - Malvern
Recruitment hospital [3] 0 0
Department of Rheumatology - Perth
Recruitment postcode(s) [1] 0 0
4558 - Cotton Tree
Recruitment postcode(s) [2] 0 0
3144 - Malvern
Recruitment postcode(s) [3] 0 0
6004 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
Rhode Island
Country [26] 0 0
United States of America
State/province [26] 0 0
South Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Rosario
Country [32] 0 0
Belgium
State/province [32] 0 0
Bruxelles
Country [33] 0 0
Belgium
State/province [33] 0 0
Leuven
Country [34] 0 0
Brazil
State/province [34] 0 0
Goiânia GO
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre RS
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo - SP
Country [37] 0 0
Canada
State/province [37] 0 0
British Columbia
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
France
State/province [40] 0 0
Marseille
Country [41] 0 0
France
State/province [41] 0 0
Nice
Country [42] 0 0
France
State/province [42] 0 0
Tours cedex 9
Country [43] 0 0
France
State/province [43] 0 0
Tours
Country [44] 0 0
Germany
State/province [44] 0 0
Aachen
Country [45] 0 0
Germany
State/province [45] 0 0
Bad Kreuznach
Country [46] 0 0
Germany
State/province [46] 0 0
Bad Segeberg
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Ellefeld
Country [49] 0 0
Germany
State/province [49] 0 0
Essen
Country [50] 0 0
Germany
State/province [50] 0 0
Klotten
Country [51] 0 0
Germany
State/province [51] 0 0
Leipzig
Country [52] 0 0
Germany
State/province [52] 0 0
München
Country [53] 0 0
Germany
State/province [53] 0 0
Nürnberg
Country [54] 0 0
Germany
State/province [54] 0 0
Steinhöring
Country [55] 0 0
Germany
State/province [55] 0 0
Tübingen
Country [56] 0 0
Germany
State/province [56] 0 0
Wiesbaden
Country [57] 0 0
Hungary
State/province [57] 0 0
Budapest
Country [58] 0 0
Hungary
State/province [58] 0 0
Debrecen
Country [59] 0 0
Hungary
State/province [59] 0 0
Györ
Country [60] 0 0
Hungary
State/province [60] 0 0
Hévíz
Country [61] 0 0
Hungary
State/province [61] 0 0
Miskolc
Country [62] 0 0
Hungary
State/province [62] 0 0
Pecs
Country [63] 0 0
Hungary
State/province [63] 0 0
Szeged
Country [64] 0 0
Hungary
State/province [64] 0 0
Veszprem
Country [65] 0 0
Hungary
State/province [65] 0 0
Ózd
Country [66] 0 0
Italy
State/province [66] 0 0
Genova
Country [67] 0 0
Italy
State/province [67] 0 0
Jesi
Country [68] 0 0
Italy
State/province [68] 0 0
Napoli
Country [69] 0 0
Italy
State/province [69] 0 0
SAN CESARIO (Lecce)
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Gyeonggi-Do
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Seoul
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Moscow
Country [73] 0 0
Taiwan
State/province [73] 0 0
Kaohsiung
Country [74] 0 0
Taiwan
State/province [74] 0 0
Taipei
Country [75] 0 0
Ukraine
State/province [75] 0 0
Dnyepropetrovsk
Country [76] 0 0
Ukraine
State/province [76] 0 0
Donetsk
Country [77] 0 0
Ukraine
State/province [77] 0 0
Kharkov
Country [78] 0 0
Ukraine
State/province [78] 0 0
Kiev
Country [79] 0 0
Ukraine
State/province [79] 0 0
Kyiv

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective
and safe three different doses of meloxicam are compared with placebo in Rheumatoid
Arthritis. Patient will take one dose of study medication daily.
Trial website
https://clinicaltrials.gov/show/NCT00042068
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim Study Coordinator
Address 0 0
Boehringer Ingelheim Ltd./Bracknell
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications